Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally

Angela K Birnbaum, Robert L. Kriel, Yoonsun Im, Rory P Remmel

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Study Objective. To determine the relative bioavailability of lamotrigine (LTG) chewable dispersible tablets after rectal administration. Design. Two-period, crossover study with a 2-week washout between dosing periods. Setting. Clinical research center. Patients. Twelve healthy adult volunteers. Intervention. One hundred milligrams of a LTG chewable dispersible tablet was administered by oral and rectal routes. Measurements and Main Results. Plasma samples were collected before and up to 120 hours after drug administration. The samples were analyzed for LTG by high-performance liquid chromatography, and the relative bioavailability was determined. Drug concentrations were lower after rectal than after oral administration. The relative bioavailability (F = AUCrectal/AUCoral) was 0.52 ± 0.23 (SD). Conclusion. Drug prepared from LTG chewable dispersible tablets is absorbed rectally, although not to the same extent as when given orally. Rectal administration of suspension of these tablets can be an acceptable route of administration.

Original languageEnglish (US)
Pages (from-to)158-162
Number of pages5
JournalPharmacotherapy
Volume21
Issue number2
DOIs
StatePublished - Jan 1 2001

Fingerprint

Biological Availability
Tablets
Rectal Administration
Pharmaceutical Preparations
Cross-Over Studies
Oral Administration
Suspensions
Healthy Volunteers
High Pressure Liquid Chromatography
lamotrigine
Research

Cite this

Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. / Birnbaum, Angela K; Kriel, Robert L.; Im, Yoonsun; Remmel, Rory P.

In: Pharmacotherapy, Vol. 21, No. 2, 01.01.2001, p. 158-162.

Research output: Contribution to journalArticle

@article{7fdefba89694447eb6080c1e10f74c9a,
title = "Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally",
abstract = "Study Objective. To determine the relative bioavailability of lamotrigine (LTG) chewable dispersible tablets after rectal administration. Design. Two-period, crossover study with a 2-week washout between dosing periods. Setting. Clinical research center. Patients. Twelve healthy adult volunteers. Intervention. One hundred milligrams of a LTG chewable dispersible tablet was administered by oral and rectal routes. Measurements and Main Results. Plasma samples were collected before and up to 120 hours after drug administration. The samples were analyzed for LTG by high-performance liquid chromatography, and the relative bioavailability was determined. Drug concentrations were lower after rectal than after oral administration. The relative bioavailability (F = AUCrectal/AUCoral) was 0.52 ± 0.23 (SD). Conclusion. Drug prepared from LTG chewable dispersible tablets is absorbed rectally, although not to the same extent as when given orally. Rectal administration of suspension of these tablets can be an acceptable route of administration.",
author = "Birnbaum, {Angela K} and Kriel, {Robert L.} and Yoonsun Im and Remmel, {Rory P}",
year = "2001",
month = "1",
day = "1",
doi = "10.1592/phco.21.2.158.34104",
language = "English (US)",
volume = "21",
pages = "158--162",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally

AU - Birnbaum, Angela K

AU - Kriel, Robert L.

AU - Im, Yoonsun

AU - Remmel, Rory P

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Study Objective. To determine the relative bioavailability of lamotrigine (LTG) chewable dispersible tablets after rectal administration. Design. Two-period, crossover study with a 2-week washout between dosing periods. Setting. Clinical research center. Patients. Twelve healthy adult volunteers. Intervention. One hundred milligrams of a LTG chewable dispersible tablet was administered by oral and rectal routes. Measurements and Main Results. Plasma samples were collected before and up to 120 hours after drug administration. The samples were analyzed for LTG by high-performance liquid chromatography, and the relative bioavailability was determined. Drug concentrations were lower after rectal than after oral administration. The relative bioavailability (F = AUCrectal/AUCoral) was 0.52 ± 0.23 (SD). Conclusion. Drug prepared from LTG chewable dispersible tablets is absorbed rectally, although not to the same extent as when given orally. Rectal administration of suspension of these tablets can be an acceptable route of administration.

AB - Study Objective. To determine the relative bioavailability of lamotrigine (LTG) chewable dispersible tablets after rectal administration. Design. Two-period, crossover study with a 2-week washout between dosing periods. Setting. Clinical research center. Patients. Twelve healthy adult volunteers. Intervention. One hundred milligrams of a LTG chewable dispersible tablet was administered by oral and rectal routes. Measurements and Main Results. Plasma samples were collected before and up to 120 hours after drug administration. The samples were analyzed for LTG by high-performance liquid chromatography, and the relative bioavailability was determined. Drug concentrations were lower after rectal than after oral administration. The relative bioavailability (F = AUCrectal/AUCoral) was 0.52 ± 0.23 (SD). Conclusion. Drug prepared from LTG chewable dispersible tablets is absorbed rectally, although not to the same extent as when given orally. Rectal administration of suspension of these tablets can be an acceptable route of administration.

UR - http://www.scopus.com/inward/record.url?scp=0035144393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035144393&partnerID=8YFLogxK

U2 - 10.1592/phco.21.2.158.34104

DO - 10.1592/phco.21.2.158.34104

M3 - Article

C2 - 11213851

AN - SCOPUS:0035144393

VL - 21

SP - 158

EP - 162

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2

ER -